UltraTech Cement
Search results
1 day ago · Mumbai: Dr Lal PathLabs, India's largest diagnostic chain, is looking at a potentially large acquisition to increase its foothold in south India. If the asset is of a strategic fit, it could look at a deal size of Rs 3,000 crore-Rs 4,000 crore, said a senior company official. "We have around Rs 1,000 crore (net) cash, we can leverage our ...
2 days ago · Dr Lal PathLabs targets 6-7% growth in patient volumes in FY25 as against a muted 2.6% rise in the previous year. The company catered to 27.6 million people in FY24 compared with 26.9 million in FY23.
1 day ago · Now, with available management bandwidth and cash reserves, Dr Lal is ready to focus on new growth opportunities. With a market capitalization of INR 27,560 Cr and a net cash position of INR 1,044 Cr as of June 30, 2024, Dr Lal PathLabs is in a strong financial position to pursue acquisitions. The company also maintains a healthy debt-equity ...
People also ask
What is Dr Lal PathLabs?
Is Dr Lal PathLabs looking for a big acquisition?
Is Dr Lal PathLabs NABL certified in India?
What is Dr Lal looking for in M&A opportunities?
1 day ago · On the intraday front, Dr Lal Pathlabs touched a high of Rs 3417, showing a 3.05% increase. This is a significant achievement for the company and reflects its strong market presence. Moreover, Dr Lal Pathlabs is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This further solidifies the company's ...
5 days ago · Get Dr. Lal Pathlabs Ltd. share price today, stock analysis, stock rating, price valuation, performance, fundamentals, market cap, shareholding, and financial report.
- ₹3,375.10 - ₹3,432.15
- Dr. Lal Pathlabs Ltd.
- The total asset value of Dr. Lal Pathlabs Ltd. stood at ₹ 2,445 Cr as on 30-Sep-23
- The share price of Dr. Lal Pathlabs Ltd. is ₹2,644.80 (NSE) and ₹2,643.05 (BSE) as of 02-Jan-2024 IST. Dr. Lal Pathlabs Ltd. has given a return of...
- Dr. Lal Pathlabs Ltd. has a market capitalisation of ₹ 21,938 Cr as on 02-Jan-2024. As per Value Research classification, it is a Mid Cap company.
- The P/B ratio of Dr. Lal Pathlabs Ltd. is 12.38 times as on 02-Jan-2024, a 0.41% premium to its peers’ median range of 8.81 times.
- The P/E ratio of Dr. Lal Pathlabs Ltd. is 72.79 times as on 02-Jan-2024, a 0.57% premium to its peers’ median range of 46.35 times.
- Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC Step...
- Dr. Lal PathLabs Limited engages in the operation of laboratories for carrying out pathological investigations in India and internationally. The co...
- The prominent promoters of Dr. Lal Pathlabs Ltd. are Name of promoters Holding percentage Arvind Lal 31.29% Vandana Lal 19.27% Archana Lal Erdma...
- The promoters of Dr. Lal Pathlabs Ltd. have pledged 0% of the total equity as on Sep-23.
4 days ago · Company profile for Dr. Lal PathLabs Limited (NSE: LALPATHLAB) with a description, list of executives, contact details and other key facts.
2 days ago · Catalog; For You; Mint Delhi. Dr Lal PathLabs chases deals in ‘tough-to-crack’ South India 2024-09-30 - Khushi Malhotra khushi.malhotra@livemint.com MUMBAI . Dr Lal PathLabs Ltd, India’s largest diagnostics chain, is looking to close deals in southern India by the end of financial year 2025 and has plans in place to double its volume growth.
